BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 34597473)

  • 21. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Panel for Immunotherapy in Low-Grade Glioma.
    Lv Q; Zhang Z; Fu H; Li D; Liu Y; Sun Y; Wu M
    World Neurosurg; 2024 Mar; 183():e825-e837. PubMed ID: 38216032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
    Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
    Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
    Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
    Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
    Su X; Li H; Chen S; Qin C
    Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.
    Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C
    Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
    Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
    J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
    Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
    Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel peroxisome-related gene signature predicts clinical prognosis and is associated with immune microenvironment in low-grade glioma.
    Gao D; Zhou Q; Hou D; Zhang X; Ge Y; Zhu Q; Yin J; Qi X; Liu Y; Lou M; Zhou L; Bi Y
    PeerJ; 2024; 12():e16874. PubMed ID: 38406287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.
    Li J; Zhang S; Chen S; Yuan Y; Zuo M; Li T; Wang Z; Liu Y
    Front Immunol; 2023; 14():1021678. PubMed ID: 36860853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
    Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
    BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma.
    Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J
    Front Immunol; 2023; 14():1220100. PubMed ID: 37662954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prognostic signature of five pseudogenes for predicting lower-grade gliomas.
    Liu B; Liu J; Liu K; Huang H; Li Y; Hu X; Wang K; Cao H; Cheng Q
    Biomed Pharmacother; 2019 Sep; 117():109116. PubMed ID: 31247469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-omics analysis-based model to predict the prognosis of low-grade gliomas.
    Du Z; Jiang Y; Yang Y; Kang X; Yan J; Liu B; Yang M
    Sci Rep; 2024 Apr; 14(1):9427. PubMed ID: 38658591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.